CHMP backs first drug for lung disease bronchiectasis Insmed gets EU recommendation for first non-cystic fibrosis bronchiectasis therapy Brinsupri, and other CHMP decisions.

#bronchiectasis #respiratory #CHMP #Insmed #brensocatib #Brinsupri #noncysticfibrosisbronchiectasis #NCFB #ASPENtrial #Sanofi #Wayrilz #rilzabrutinib #immunethrombocytopenia #ITP #SanofiWinthrop #Rezurock #belumosudil #chronicgraftversushostdisease #GvHD #transplant #KadmonPharma
zurl.co/r27x2

FDA clears Sanofi’s Wayrilz as first for rare blood disorder The US regulatory agency approves Sanofi’s Wayrilz as the first BTK inhibitor for treating persistent or chronic immune thrombocytopenia.

🚨 FDA approval alert: Sanofi’s Wayrilz (rilzabrutinib) becomes the first BTK inhibitor for adults with chronic immune thrombocytopenia (ITP). Backed by strong Phase 3 data, this marks a new era in rare blood disorder care.

#News #Wayrilz #FDAApproval #ITP #RareDisease #Hematology #BTKinhibitor

FDA clears Sanofi’s Wayrilz as first for rare blood disorder The US regulatory agency approves Sanofi’s Wayrilz as the first BTK inhibitor for treating persistent or chronic immune thrombocytopenia.

🚨 FDA approval alert: Sanofi’s Wayrilz (rilzabrutinib) becomes the first BTK inhibitor for adults with chronic immune thrombocytopenia (ITP). Backed by strong Phase 3 data, this marks a new era in rare blood disorder care.

#News #Wayrilz #FDAApproval #ITP #RareDisease #Hematology #BTKinhibitor